As the demand for GLP-1 drugs for obesity management escalates, the US healthcare system is grappling with a crisis. Patients are being forced to pivot due to restrictions on coverage, which has led to concerns among health advocates that cuts in Medi-Cal funding for these medications could exacerbate health disparities, particularly in California. Amidst this turbulent landscape, a CEO is striving to provide employees with access to weight loss drugs, yet the exorbitant costs present a significant barrier to this initiative.